Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193497 | 0.80 | KMT2A (0.62) | ABCG2MAPTALDH1A1KDM4ESTK33 | |
| SCHEMBL2740273 | 0.74 | STK33 (0.54) | KDRSIRT1MAPTHPGDALDH1A1 | |
| SCHEMBL28555588 | 0.73 | KDR (0.57) | ABCG2KDRHPGDSTK33TP53 | |
| SCHEMBL13522985 | 0.73 | SGMS2 (0.57) | HSD17B10SGMS2HPGDALDH1A1KDM4E | |
| SCHEMBL2740127 | 0.72 | SIRT1 (0.68) | KDRSIRT1HSD17B10MAPTHPGD | |
| SCHEMBL6067716 | 0.72 | HDAC1 (0.66) | ABCG2MAPTHPGDTP53NPC1 | |
| SCHEMBL12750105 | 0.71 | SGMS2 (0.55) | HSD17B10SGMS2HPGDALDH1A1KDM4E | |
| SCHEMBL995824 | 0.71 | HDAC6 (0.79) | KDRHSD17B10MAPTALDH1A1KDM4E | |
| SCHEMBL13916713 | 0.70 | SGMS2 (0.56) | HSD17B10SGMS2MAPTHPGDALDH1A1 | |
| SCHEMBL11644616 | 0.70 | SGMS2 (0.57) | HSD17B10SGMS2MAPTHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2019-07-25 | — | — | US | disclosed |
| US-9855235-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-9351967-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-4131677-A | Anti-inflammatory oxazolo [5,4-b]pyridines | MERCK & CO., INC. (US) | 1978-12-26 | — | — | US | disclosed |
| US-4038396-A | ANTIPYRETICS, ANALGESICS | MERCK & CO., INC. (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | ABCG2 3768/4885KDR 645/4885SIRT1 2/4885 |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | ABCG2 4650/4885KDR 3552/4885SIRT1 5/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | ABCG2 3971/4885KDR 1539/4885SIRT1 1/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | ABCG2 3790/4885KDR 655/4885SIRT1 2/4885 |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | ABCG2 4650/4885KDR 3552/4885SIRT1 5/4885 |
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | PC, HADHB, ACACB | ABCG2 4650/4885KDR 3552/4885SIRT1 5/4885 |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | ABCG2 4650/4885KDR 3552/4885SIRT1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.